Ob/Gyn Groups Oppose Insurer Prior Authorization, Counseling Rules For Genetic Tests
This article was originally published in The Gray Sheet
Obstetrician/gynecology groups issued a joint statement opposing health insurer requirements for prior authorization and genetic counseling for coverage of frequently used genetic tests to determine breast and ovarian cancer status, including BRCA1 and BRCA2.
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.